We diagnose to cure
Our blood-based approach unlocks true precision medicine
Our blood-based platform unlocks true precision medicine
Big data diagnostics, AI, and therapeutics working in tandem for patients
Diagnostics
Blood-based diagnostics with multiomic data, including genomics and transcriptomics, provide a more detailed understanding of disease
Data + AI
Analyzing multiomic patient data from all stages leads to disease insights and novel targets
Therapeutics
A deeper understanding of disease biology unlocks new, better drug targets and medicines
Standard noninvasive blood draw
Our technology works with routine blood draws, replacing the need for invasive bone marrow biopsies.
Blood-based multiomic diagnostics
Multiomic analysis enables early detection, accurate diagnosis, improved treatment guidance, and monitoring.
Growing patient database
The more patient data we collect and analyze, the more powerful our diagnostic and therapeutic discovery tools become.
Our AI/ML mines data to identify therapeutic approaches
By combining computational and statistical approaches, we analyze genetic and multiomic data from each patient to provide personalized treatment guidance, disease pathways insights, and new therapeutic targets.
Deliver novel therapeutics
We focus on identifying the most effective therapy for each individual patient.
Cancer cell death
Helping patients choose the best treatment leads to longer lives.
Solving big problems in cancer care
Early interception + dynamic monitoring
Our blood-based platform is more sensitive and more informative than existing bone marrow tests for accurate diagnosis and earlier interception of disease. Ongoing monitoring through regular blood draws enables earlier detection of disease so physicians can respond sooner.
Personalized treatment guidance
Concise reports deliver actionable insights about which therapies are most likely to succeed and maximize patients’ lives.
Harnessing patient data to make better medicines
We’re amassing the most comprehensive multiomic database in blood cancer, which we mine using AI to uncover insights into disease biology and potential novel therapies.
The Team
Predicta is guided by a veteran leadership team with decades of commercialization experience across genomics, oncology, and diagnostics.
Kate Caves
CEO
Aparna Raval
SVP, Translational Research
Francois Aguet, PhD
Head of Computational Biology
Doron Lipson, PhD
CTO
The Board
Mara Aspinall
Partner, Illumina Ventures
Jay Wohlgemuth, MD
Independent, Former CMO Quest Diagnostics
Ann DeWitt, PhD
Partner, Engine Ventures
Kate Caves
CEO
Irene Ghobrial, MD
Professor of Medicine, Dana Farber Cancer Institute, Harvard Medical School
Scientific Co-founders
Predicta was founded by the world’s leading cancer genomics and multiple myeloma researchers from the Broad Institute and Dana Farber Cancer Institute – many are physician scientists who see patients every day.
Kenneth Anderson, MD
Professor of Medicine, Dana Farber Cancer Institute, Harvard Medical School, Co-founder of C4 Therapeutics
Irene Ghobrial, MD
Professor of Medicine, Dana Farber Cancer Institute, Harvard Medical School
Gad Getz, PhD
Professor of Pathology, Mass General, Harvard Medical School, Co-founder of the Broad Institute and Scorpion Therapeutics
Keith Flaherty, MD
Professor of Medicine, Mass General, Harvard Medical School, Founder of Loxo Oncology, Strata Oncology, Scorpion Therapeutics
Romanos Sklavenitis-Pistofidis, MD, PhD
Instructor of Medicine, Dana-Farber Cancer Institute, Harvard Medical School
Predicta is backed by leading life sciences investors
Contact us
Thank you
Your submission has been received.